Curevac announces financial results for the first quarter of 2022 and provides business update

Progressing broad vaccine development program in collaboration with gsk, with second-generation candidates in phase 1 clinical trials for covid-19 and influenza curevac eligible to a €10 million milestone payment from gsk for the initiation of the influenza clinical trial increasing momentum in oncology with access to neoantigen technologies to feed meaningful pipeline of cancer vaccine candidates partnership with myneo to develop novel mrna cancer vaccines leveraging myneo's advanced platform for tumor antigen discovery and selection cash position of €658.2 million as of march 31, 2022, impacted by wind-down costs for first-generation covid-19 vaccine program tÜbingen, germany and boston ma / accesswire / may 25, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced financial results for the first quarter of 2022 and provided a business update.
CVAC Ratings Summary
CVAC Quant Ranking